Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

BACKGROUND: Capecitabine plus oxaliplatin (XELOX) has been established as a first-line treatment for metastatic colorectal cancer. Adherence is particularly important with capecitabine to maintain appropriate curative effect. In this study, we monitored the adherence to capecitabine on XELOX treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakami, Kazuyoshi, Nakamoto, Eri, Yokokawa, Takashi, Sugita, Kazuo, Mae, Yutarou, Hagino, Akane, Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Oniyama, Sayaka, Machida, Yoshiaki, Yamaguchi, Toshiharu, Hama, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399552/
https://www.ncbi.nlm.nih.gov/pubmed/25914526
http://dx.doi.org/10.2147/PPA.S80327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399552/
https://www.ncbi.nlm.nih.gov/pubmed/25914526
http://dx.doi.org/10.2147/PPA.S80327

Ejemplares similares